UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Gary Schiller, M.D., F.A.C.P.

Specialty:

Hematologic Oncology

Hematology

General Information:

Gender:	Male
Language(s):	English, Spanish, Hebrew, German

Affiliation(s):

Professor, Department of Medicine, Hematology/Oncology

Physician, Department of Pathology and Laboratory Medicine, Laboratory Medicine, Therapeutic Hemapheresis, Transfusion Medicine

Director, Hematological Malignancies/Stem Cell Transplantation Unit

Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:	Medicine, Hematology/Oncology, UCLA School of Medicine, 1987 - 1990
Residency:	Internal Medicine, UCLA School of Medicine, 1985 - 1987
Internship:	Internal Medicine, UCLA School of Medicine, 1984 - 1985
Medical Degree:	M.D., USC School of Medicine, 1984

Certification(s):

Medical Board Certification(s):	Hematology, American Board of Internal Medicine, 1990 Medical Oncology, American Board of Internal Medicine, 1989 Internal Medicine, American Board of Internal Medicine, 1987

Contact Information:

Hematology/Oncology:	(310) 206-6909 Information and patient appointments
UCLA Oncology Center:	(310) 206-6931 Information and patient appointments
Therapeutic Hemapheresis:	(310) 794-7177 Information and referral
Transfusion Medicine:	(310) 825-4968 Information and referral
Email:	gschiller@mednet.ucla.edu

Practice Information:

Clinical Interest(s):	Antiphospholipid Bone Marrow Transplantation Chronic Myelogenous Leukemia General Hematology Hematologic Malignancies Leukemia Lymphoma Multiple Myeloma Myelodysplasia Stem Cell Transplant Breast

Scientific Interest(s):

Dr. Gary Schiller's research projects include: clinical studies of new drugs, therapies and bone marrow transplantation for patients with malignancies of the blood or bone marrow such as leukemia, multiple myeloma and lymphoma.

Schiller has carried out studies of stem cell transplantation following high-dose chemotherapy and radiation for acute myelogenous leukemia, one of the most common types of leukemia in adults. Schiller has also carried out work with purified stem cell transplantation for multiple myeloma. He and his colleagues are conducting ongoing studies using new drugs and therapeutics for chronic lymphocytic leukemia, chronic myelogenous leukemia and multiple myeloma. The researchers are also studying certain kinds of non-Hodgkin's lymphoma. Schiller's approach is to put into clinical trials new treatments developed in the laboratory for patients with blood stem cell diseases or cancers of the bone marrow and blood.

Selected Cancer-Related Publications:

Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006; 107(1): 293-300.

Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42(12): 1726-34.

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006; 24(16): 2456-64.

Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2006; 12(4): 466-71.

Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 2006; 108(8): 2745-54.